
May 12 (Reuters) - CytomX Therapeutics Inc CTMX.O:
CYTOMX ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 1 DOSE ESCALATION STUDY OF EPCAM ANTIBODY DRUG CONJUGATE (CX-2051) CANDIDATE IN PATIENTS WITH ADVANCED COLORECTAL CANCER (CRC)
CYTOMX THERAPEUTICS INC - PLANNING PHASE 2 STUDY INITIATION IN 1H 2026
CYTOMX THERAPEUTICS INC - CX-2051 HAS BEEN GENERALLY WELL TOLERATED